We will know even more about the company's prospects in a year as it releases clinical data for various pipeline candidates.

Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing ...

Earlier in March 2026, CRISPR Therapeutics completed a US$550 million private offering of 1.7308% Convertible Senior Unsecured Notes due March 1, 2031, issued under Rule 144A to bolster its funding ...

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

Genomics (NasdaqGS:TXG) is collaborating with PerturbAI, NVIDIA, and the Allen Institute on what is described as the largest in vivo CRISPR brain atlas. The partnership combines 10x Genomics' single ...

A vanadium MXene nanoparticle uses gene editing to strip tumors of heat resistance, then kills them with laser-triggered free ...

CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

The field of plant biotechnology has quickly evolved with the advent of CRISPR-mediated gene editing, fundamentally transforming the exploration and ...

Neither the Parties nor the Patent Trial and Appeal Board (PTAB) have been resting in addressing the decision by the Federal Circuit that vacated ...